AVL-292 is a selective, orally administered, inhibitor of Bruton’s tyrosine kinase (Btk). The expression of Btk is found on B-lymphocytes and has been implicated in the growth and survival of certain B-cell lymphomas as well as in CLL. This is a Phase Ib, escalating dose study of AVL-292 as a monotherapy in subjects with relapsed and/or refractory B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom’s macroglobulinemia
GA101 is a humanized third generation monoclonal antibody that binds to CD20, expressed in cancerous B cells. In preclinical studies it shows greater antibody-dependent cellular cytotoxicity than other CD20 antibodies and can so be potentially more effective. In this Phase II study GA101 is administered in combination with CHOP chemotherapy in patients with previously untreated advanced diffuse large B-cell lymphomas.
MLN8237 is an oral selective small molecule inhibitor for Aurora A kinase. Aurora A kinase has a regulatory roll in cell mitosis and is over-expressed in many tumors. In this Phase II study MLN8237 is taken twice a day on days 1-7 every three weeks by patients with relapsed or refractory peripheral T-cell Non-Hodgkin lymphoma.